$MSLE News

HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $11 Price Target

Satellos Bioscience Q1 EPS $(0.53) Down From $(0.44) YoY

Guggenheim Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $23

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $11

Satellos Bioscience: Q4 Earnings Snapshot

Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

Cantor Fitzgerald Initiates Coverage On Satellos Bioscience with Overweight Rating

Satellos Bioscience shares are trading lower after the company announced interim clinical and biomarker data for SAT-3247.

Satellos Bioscience shares are trading lower after the company announced interim clinical and biomarker data for SAT-3247.

Satellos Up Near 10% In US Premarket As Presents Interim SAT-3247 Clinical and Biomarker Data in DMD at Florida Conference

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Satellos Presents Interim Phase 2 SAT-3247 Duchenne Data Showing Continued Handgrip Strength Improvement, Stable Upper Limb Strength And Biomarker Reductions, With Enrollment Ongoing In TRAILHEAD And BASECAMP

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

Satellos to Participate in Upcoming Investor Conferences

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

Satellos price target raised to $40 from $5 at Oppenheimer

Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Satellos Closes US$57.2 Million Public Offering in Canada and the United States